BioSpace News Archive

California Protons Cancer Therapy Center announced the treatment of its 3,000th patient with proton therapy since the Center opened in 2014.

Consumer demand for virtual health care has exploded during the COVID-19 pandemic. Thanks to telemedicine, patients with new concerns and those with chronic conditions can have an appointment with a board-certified physician from the comfort and safety of their homes.

Zero Gravity Solutions, Inc., an agricultural biotechnology company, is expanding upon its previously announced collaboration between its wholly-owned subsidiary, BAM Agricultural Solutions, Inc., and the National Black Farmers’ Association with Dr. John W. Boyd, Jr.

The Advancing CGT Virtual Event presented by GENEWIZ and Brooks Life Sciences, opens on April 7-8, 2021 and aims to discuss the opportunities, challenges, and latest technology breakthroughs in cell and gene therapy.

FibroGen, Inc. provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease.

MicroGenDX, the industry leader in providing Next Generation DNA Sequencing (NGS) for clinical diagnostics, now offers COVID-19 Variant ID, a whole genome sequencing service for identifying known variants of SARS-CoV-2 described by the CDC as epidemiologically significant

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, plans to release its first quarter 2021 results after the financial markets close on Wednesday, May 5, 2021.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Organon Finance 1 LLC plans to offer, subject to market conditions, euro-denominated senior secured notes due 2028, U.S. dollar-denominated senior secured notes due 2028 and U.S. dollar-denominated senior unsecured notes due 2031 (collectively, the “notes”), in connection with the previously announced spinoff of Organon & Co.

BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on April 5, 2021, the compensation committee of BridgeBio’s board of directors granted 19 new employees restricted stock units for an aggregate of 32,691 shares of the Company’s common stock.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the commencement of a proposed underwritten public offering of 2,500,000 shares of its common stock by Outset and 2,500,000 shares of its common stock by certain of its stockholders.